In particular, the consistent findings of the highly pleiotropic oncosuppressive role of RNASET2 in ovarian cancer (acting at both cell-autonomous and noncell-autonomous levels and thereby targeting both cancer cells and a key component of the TME innate immune system such as tissue macrophages) hold great potential for the introduction of this multi-faceted oncosuppressor protein in the setting of innovative molecules endowed with the ability to hamper cancer cell growth on multiple levels of action. This evidence concerns the gene RNASET2 and ovarian carcinoma.